Mouse Eosinophilic Gastroenteritis (EGE) Models

Eosinophilic gastroenteritis (EGE) is a rare digestive disorder characterized by eosinophilic infiltration in the stomach and intestinal walls, leading to abdominal pain, nausea, vomiting, and weight loss. The pathogenesis involves hypersensitivity responses, often associated with food allergies, asthma, or eczema. HKeyBio offers a well-validated mouse EGE model induced by ovalbumin (OVA) in BALB/c mice. This model recapitulates key features of human EGE, including body weight loss, eosinophilic infiltration in intestinal tissues, elevated inflammatory cells in blood, and destruction of intestinal villi and crypts. It provides a robust platform for preclinical efficacy testing of novel therapeutics for eosinophilic gastrointestinal disorders.

Quantity:
Availability:





Inquire Add to Basket

Product Description

Key Features & Benefits

Clinically relevant – Mimics human EGE: weight loss, eosinophilic infiltration in gastrointestinal tract, and allergic inflammation.

Well-characterized endpoints – Body weight, blood cell counts (WBC, Neu, Eos), tissue eosinophil quantification, intestinal histopathology, OVA-specific antibodies.

Translational value – Ideal for testing anti-eosinophil therapies (anti-IL-5, anti-IL-5Rα), steroids, and biologics targeting Th2 inflammation.

Mechanistic insights – Enables study of eosinophil recruitment, Th2 cytokine responses, and food allergy mechanisms.

IND-ready data packages – Studies can be conducted in accordance with GLP principles.

Technical Data & Validation

Representative data from our OVA Induced BALB/c EGE model:

OVA Induced BALB/c EGE Model

ef3bc4d1a3aa1937e61dc77f01feef05

Applications

• Efficacy testing of anti-eosinophil therapies (anti-IL-5, anti-IL-5Rα, anti-Siglec-8), corticosteroids, and biologics targeting Th2 inflammation

• Target validation for eosinophil recruitment and Th2 cytokine pathways

• Food allergy and eosinophilic gastrointestinal disorder research

• Mechanism of action (MOA) studies

• IND-enabling pharmacology and toxicology studies

Model Specifications

Parameter	Specification
Species/Strain	BALB/c mouse
Induction method	OVA sensitization (with alum adjuvant, intraperitoneal) followed by intragastric OVA challenges
Study duration	4–8 weeks (primary and secondary response assessment)
Key endpoints	Body weight, blood cell counts (WBC, Neu, Eos), eosinophil infiltration in stomach/intestine (histology), OVA-specific IgG/IgE, intestinal histopathology score (villus height, crypt depth, inflammatory infiltration)
Data package	Raw data, analysis reports, flow cytometry files, bioinformatics (optional)

❓ Frequently Asked Questions

Q1: What EGE preclinical model do you provide?

A1: We offer an OVA-induced eosinophilic gastroenteritis model using BALB/c mice for related disease research and drug screening.

Q2: What is the modeling mechanism?

A2: OVA sensitization and challenge trigger abnormal Th2 immune responses, causing intestinal and gastric mucosal inflammation as well as massive eosinophil infiltration, which mimics the pathological features of human EGE.

Q3: What evaluation indicators are used?

A3: We monitor body weight, perform flow cytometry analysis, detect eosinophils and T cells, and conduct HE staining to assess gastric pathological lesions.

Q4: What is the experimental procedure and cycle?

A4: OVA sensitization is carried out from Day 14 to Day 28, followed by OVA challenge every two days. The whole experiment lasts 38 days.

Q5: What are the advantages and applications?

A5: This model has stable inflammatory phenotypes and obvious eosinophil infiltration. It is widely applied for efficacy verification and mechanism study of drugs treating eosinophilic gastroenteritis.